Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39753110.
- Also identified by DOI 10.1016/j.stem.2024.12.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Since the first derivation of human pluripotent stem cells (hPSCs) 27 years ago, technologies to control their differentiation and manufacturing have advanced immensely, enabling increasing numbers of clinical trials with hPSC-derived products. Here, we revew the landscape of interventional hPSC trials worldwide, highlighting available data on clinical safety and efficacy. As of December 2024, we identify 116 clinical trials with regulatory approval, testing 83 hPSC products. The majority of trials are targeting eye, central nervous system, and cancer. To date, more than 1,200 patients have been dosed with hPSC products, accumulating to >10<sup>11</sup> clinically administered cells, so far showing no generalizable safety concerns.
Medical subject headings
- Cell- and Tissue-Based Therapy
- Clinical Trials as Topic
- Pluripotent Stem Cells